Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier.
A novel and improved vaccine delivery system and/or adjuvant is actively sought to enhance the potency of vaccines. Previously, we reported that strong antitumor immunity could be generated when a peptide antigen was incorporated into LPD (cationic liposome-polycation-pDNA) nanoparticles. In this study, we found that both the cationic liposome and DNA are required for the full immunostimulation activity of LPD. The unique ability of LPD to readily move into local lymphoid tissues and to activate antigen-presenting cells might be responsible for its strong immunostimulatory activity. Moreover, cationic liposome stimulates the expression of CD80/CD86 on dendritic cells (DCs), but not the release of TNF-alpha from DCs, suggesting the existence of a NF-kappaB-independent immunostimulation pathway for cationic lipids such as DOTAP.
Cui
Zhengrong
Z
Center for Pharmacogenetics, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15213, USA. zhengrong.cui@oregonstate.edu
Han
Su-Ji
SJ
Vangasseri
Dileep Padinjarae
DP
Huang
Leaf
L
D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology; D015703:Antigens, CD / Q000378:metabolism; D018122:B7-1 Antigen / Q000276:immunology; D051940:B7-2 Antigen; D002460:Cell Line; D002784:Cholesterol / Q000008:administration & dosage; D003601:Cytotoxicity Tests, Immunologic; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology; D004338:Drug Combinations; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage; D005260:Female; D007114:Immunization; D007371:Interferon-gamma / Q000378:metabolism; D008081:Liposomes / Q000008:administration & dosage*; D008156:Luciferases / Q000378:metabolism; D008198:Lymph Nodes / Q000276:immunology; D008221:Lymphoid Tissue / Q000276:immunology; D008562:Membrane Glycoproteins / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D049329:Nanostructures; D010080:Oxazoles / Q000008:administration & dosage; D010957:Plasmids; D011479:Protamines / Q000008:administration & dosage*; D011744:Pyrimidinones / Q000008:administration & dosage; D000644:Quaternary Ammonium Compounds / Q000008:administration & dosage; D013154:Spleen / Q000166:cytology / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D019444:Vaccines, DNA / Q000008:administration & dosage*
D015703:Antigens, CD; D018122:B7-1 Antigen; D051940:B7-2 Antigen; C497965:Cd86 protein, mouse; D004338:Drug Combinations; D005229:Fatty Acids, Monounsaturated; D008081:Liposomes; D008562:Membrane Glycoproteins; D010080:Oxazoles; D011479:Protamines; D011744:Pyrimidinones; D000644:Quaternary Ammonium Compounds; D014409:Tumor Necrosis Factor-alpha; D019444:Vaccines, DNA; C063359:2,3-dihydro-5H-oxazolo(3,2-a)thieno(3,2-d)pyrimidin-5-one; D007371:Interferon-gamma; D002784:Cholesterol; D008156:Luciferases; C070046:1,2-dioleoyloxy-3-(trimethylammonium)propane